Ryvu Therapeutics S.A.

LSE:0RKT Stock Report

Market Cap: zł861.2m

Ryvu Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Pawel Przewiezlikowski

Chief executive officer

zł1.1m

Total compensation

CEO salary percentage78.4%
CEO tenureno data
CEO ownership17.4%
Management average tenure3.3yrs
Board average tenure5.3yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Pawel Przewiezlikowski's remuneration changed compared to Ryvu Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-zł104m

Jun 30 2024n/an/a

-zł96m

Mar 31 2024n/an/a

-zł94m

Dec 31 2023zł1mzł838k

-zł92m

Sep 30 2023n/an/a

-zł73m

Jun 30 2023n/an/a

-zł66m

Mar 31 2023n/an/a

-zł75m

Dec 31 2022zł341kzł165k

-zł84m

Sep 30 2022n/an/a

-zł94m

Jun 30 2022n/an/a

-zł105m

Mar 31 2022n/an/a

-zł92m

Dec 31 2021zł1mn/a

-zł79m

Sep 30 2021n/an/a

-zł72m

Jun 30 2021n/an/a

-zł61m

Mar 31 2021n/an/a

-zł41m

Dec 31 2020n/an/a

-zł32m

Sep 30 2020n/an/a

-zł40m

Jun 30 2020n/an/a

-zł32m

Mar 31 2020n/an/a

-zł41m

Dec 31 2019zł524kzł524k

-zł44m

Sep 30 2019n/an/a

-zł53m

Jun 30 2019n/an/a

-zł60m

Mar 31 2019n/an/a

-zł28m

Dec 31 2018zł476kzł476k

-zł23m

Compensation vs Market: Pawel's total compensation ($USD256.56K) is below average for companies of similar size in the UK market ($USD709.60K).

Compensation vs Earnings: Pawel's compensation has increased whilst the company is unprofitable.

CEO

Pawel Przewiezlikowski

no data

Tenure

zł1,068,120

Compensation

Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...

Leadership Team

NamePositionTenureCompensationOwnership
Pawel Przewiezlikowski
Founderno datazł1.07m17.37%
PLN 149.6m
Krzysztof Brzózka
Executive VP13yrszł1.43m1.16%
PLN 10.0m
Kamil Sitarz
COO & Member of the Management Board4.2yrszł1.18m0.17%
PLN 1.5m
Vatnak Vat-Ho
Chief Business Officer & Member of Management Board2.4yrszł2.22m0.25%
PLN 2.1m
Hendrik Nogai
Chief Medical Officer & Member of Management Board2.4yrszł2.17m0.058%
PLN 502.9k
Paulina Wolanin
Human Resources Managerno datano datano data

3.3yrs

Average Tenure

Experienced Management: 0RKT's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Smith
Member of Supervisory Board1.6yrszł90.15kno data
Rafal Chwast
Independent Member of the Supervisory Boardno datazł159.99k0.52%
PLN 4.5m
Tadeusz Wesolowski
Non-Independent Vice Chairman of Supervisory Boardno datazł157.23k0.40%
PLN 3.5m
Scott Fields
Member of Supervisory Board1.6yrszł121.27kno data
Piotr Romanowski
Independent Chairman of the Supervisory Board14yrszł159.78k0.22%
PLN 1.9m
Axel Glasmacher
Non-Independent Member of the Supervisory Board5.3yrszł157.23kno data
Thomas Turalski
Non-Independent Member of the Supervisory Board5.3yrszł157.23k0.087%
PLN 748.7k

5.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 0RKT's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 07:36
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Jonas PeciulisEdison Investment Research